Short answer
ACCENDRA HEALTH INC/VA/ (ACH) filed an 8-K current report with the SEC on May 11, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure). Comprehensive debt restructuring: $326.25M of 9.000% first-lien notes due 2032 plus 9.750% second-lien notes due 2033.
ACCENDRA HEALTH INC/VA/ 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Comprehensive debt restructuring: $326.25M of 9.000% first-lien notes due 2032 plus 9.750% second-lien notes due 2033
- $261.0M first-lien backstop commitment at par, with up to $65.25M additional capacity and a 3.50% cash backstop fee
- $300.0M new revolving facility due 2030, subject to 91-day springing maturity if intervening debt exceeds $25.0M
- Proceeds and cash earmarked to repay Term A and existing revolver borrowings, potentially extending liquidity but increasing secured debt costs
- Existing note covenants substantially weakened, while $400.0M asset-sale mandatory prepayment waiver supports transaction execution
Item 7.01 · Regulation FD Disclosure
- Filing contains only Item 9.01 exhibit and signature material, not substantive Regulation FD disclosure
- Accelmed Health agreed to furnish omitted schedules or exhibits to the SEC upon request
- Report signed May 11, 2026 by Heath H. Galloway, Executive Vice President, General Counsel and Corporate Secretary
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ACCENDRA HEALTH INC/VA/ 8-K filings
Get the next ACH 8-K as it lands
Follow ACH for push alerts, or ask the research agent what this filing means.